Long-term behavior of endothelial and coagulation markers in Eisenmenger syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 2, 2006, Pages 175-183

  Caramuru, Lúcia H ^a   Lopes, Antonio Augusto ^a   Maeda, Nair Y ^b   Aiello, Vera D ^a   Filho Cavalheiro, Cyrillo ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Molecular Biology Division   (Brazil)

Author keywords

Eisenmenger syndrome; Endothelial dysfunction; Endothelial markers; Erythrocytosis; Hypoxia; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; BIOCHEMICAL MARKER; D DIMER; DIURETIC AGENT; IRON; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN; BIOLOGICAL MARKER; OXYGEN;

ADULT; ARTICLE; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; RISK FACTOR; SYMPTOM; THROMBOSIS; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; ADOLESCENT; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; TIME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; CHILD; CHILD, PRESCHOOL; EISENMENGER COMPLEX; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXYGEN; THROMBOSIS; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 33747768614     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200205     Document Type: Article

References (31)

1. Vongpatanasin W, Brickner E, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128:745.
2. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538.
3. Perloff JK, Hart EM, Greaves SM, et al. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003;92:182.
4. Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003;42:1982.
5. Caramurú LH, Maeda NY, Bydlowski SP, et al. Age-dependent likelihood of in situ thrombosis in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2004;10:217.
6. Eisenberg PR, Lucore C, Kaufman L, et al. Fibrinopeptide. A level indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990;82:841.
7. Huber K, Beckmann R, Frank H, et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994;150:929.
8. Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996;19:549.
9. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356.
10. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110:710.
11. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998;9:10.
12. Farber HW, Loscalzo J. Prothrombotic mechanism in primary pulmonary hypertension. J Lab Clin Med 1999;134:561.
13. Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 1999;44:274.
14. Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001;120:1226.
15. Shitrit D, Bendayan D, Baar-Gil-Shitrit A, et al. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002;122:1674.
16. Cacoub P, Karmochkine M, Dorent R, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996;101:160.
17. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782.
18. Gonçalves RC, Buschpigell CA, Lopes AA. Circulating blood volumes in pulmonary hypertension associated with erythrocytosis - the effects of therapeutic hemodilution. Cardiol Young 2003;13:544.
19. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346.
20. Ruggeri ZM. Structure and biosynthesis of von Willebrand factor. In: Ruggeri ZM, ed. von Willebrand Factor and the Mechanism of Platelet Function. Berlin: Springer, 1998:33.
21. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies: A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996;97:493.
22. Pepper MS, Rosnoblet C, Di Sanza C, et al. Synergistic induction of tissue-type plasminogen activator (tPA) by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thromb Haemost 2001;86:702.
23. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: Initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000;1497:1.
24. Wu KK, Matijevic-Aleksic N. Thrombomodulin: A linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann Med 2000;32:73.
25. Takahashi H, Ito S, Hanano M, et al. Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992;41:32.
26. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the atherosclerosis risk in communities (ARIC)) study: A case-cohort study. Lancet 1999;353:1729.
27. Ogawa S, Gerlach H, Esposito C, et al. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. J Clin Invest 1990;85:1090.
28. Uchiyama T, Kurabayashi M, Ohyama Y, et al. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1155.
29. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580.
30. Schamroth CL, Sareli P, Pocock WA, et al. Pulmonary arterial thrombosis in secundum atrial septal defect. Am J Cardiol 1987;60:1152.
31. Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: Ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999;34:232.